FDA Approves New Boston Scientific Heart Stent

The FDA has cleared Boston Scientific's Promus Element Plus chromium heart stent, according to a Wall Street Journal report.

The company expects the approval will add $200 million to annualized gross margin in the United States and Japan by the end of 2012.

The early approval might allow the company to record a pretax charge of $40 million during the fourth quarter of this year.

Related Articles on Medical Device Approvals:

FDA Clears Aptus Endosystems EndoStapling System
FDA Approves Carestream's Vue Motion Medical Image Viewer
FDA Approval for Edwards' Sapien Device is a First for U.S. Market

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers